Transient transfection at large scale for clinical AAV9 vector manufacturing
AAV9 production in adherent HEK293 cells was scaled from the pilot iCELLis® Nano bioreactor to the large scale iCELLis 500 bioreactor (200 m2 and 333 m2 surface area). A HEK293 cell seed train was utilized, using the Xpansion® 200 bioreactor. Media components were evaluated and replenished as needed throughout the run using the perfusion process of the iCELLis bioreactor. Following a production phase, >1016 vector genomes were isolated from crude harvest of the bioreactor.
Speaker
Rachel Legmann, PhD
Transient transfection at large scale for clinical AAV9 vector manufacturing
Learn about scalable, single-use solutions for purification of viral vectors
Watch Todd Sanderson’s video presented during ICST 2020 Virtual event.
Biotech | Pall Corporation webinar series
Integrity Assurance for Single-Use Systems An End-User’s Perspective
What should you consider when building an integrity control strategy for your single-use systems (SUS)? How do you overcome application challenges?
Join leading industry experts Charlotte Masy of GSK and Patrick Evrard from Pall Corporation to gain insights and answers in this webinar from BioPharma Asia on integrity Assurance for Single-Use Systems, an End-User’s Perspective. They will present several case studies to show how integrity concerns can be practically addressed for cGMP manufacturing applications and the results observed a few years on.
Attendees will learn about:
- The latest regulatory requirements for integrity assurance of SUS
- The different technologies available to control integrity of SUS
- Key parameters that affect integrity measurements
Register now for this webinar from industry experts on October 6.